Clinical Trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Study acronym: AMPLITUDE
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Protocol Amendment History 93 amendments
This ClinicalTrials.gov record has been amended 93 times since 2022-03-28; most recent amendment 2026-06-24.
Status change: Not Yet Recruiting → Recruiting 2022-04-20
Trial Details
NCT Number NCT05312879
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Proteinuric Kidney Disease
Enrollment 466 participants
Start Date 2022-03-30
Primary Completion 2028-06-02 (estimated)
Study Completion 2030-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-04